Preliminary Full Year 2021 Product Sales were approximately $40.1 million, including core non-COVID-19 sales growth of approximately 13% from 2020. Cumulative CytoSorb treatments surpassed 162,000.
Third Quarter 2021 total revenue was $9.8 million, including product sales of $8.9 million. Core non-COVID-19 product sales increased 3% Y-Y to approximately $7.8 million.